Since March, the rate at which European patents granted by the European Patent Office (EPO) are converted to Unitary Patents has risen from 18% to 243%, an increase of 35% The figures… read more…
On 19 July 2024, the Court of Appeal under Lord Justice Birss handed down its judgement on the case of Comptroller – General of Patents, Designs and Trade Marks v Emotional Perception AI Limited… read more…
The EPO Board of Appeal in decision T 0439/22 of 24 June 2024 referred new questions to the Enlarged Board of Appeal on whether and to what extent the description and drawings can be taken into… read more…
Mathys & Squire Partners Laura Clews and Chris Hamer were recently interviewed by Protein Production Technology International (PPTI) and provided commentary on various issues relating to… read more…
Commentary by Partner Andrew White has been featured in Law 360, Solicitors Journal, The Patent Lawyer and The Global Legal Post, discussing how an increase in defence spending is thought to be… read more…
Introduction In April 2023 the EU published draft legislation which, if enacted, would represent a major shift in the regulatory and IP framework for pharmaceutical products in Europe[1] As… read more…
Mathys & Squire attorneys: David Hobson, Martin MacLean and Nicholas Fox have filed a Petition for Review on behalf of Ipsen Bioinnovation asking the European Patent Office’s (EPO)… read more…
Mathys & Squire is pleased to be ranked as a leading European patent law firm by the Financial Times (FT) in their 2024 report Mathys & Squire has also been highlighted in five… read more…
Mathys & Squire is thrilled to be ranked in the 2024 edition of IAM Patent 1000: The World’s Leading Patent Professionals IAM is known for being the definitive resource outlining… read more…